Palatin fattens coffers for research

Contrast agent developer Palatin Technologies has raised $11.5 million through the private placement of securities to institutional and accredited investors. The Cranbury, NJ-based firm said it would use the proceeds primarily to advance the development of its LeuTech infection imaging agent and further development of its PT-141 drug for the treatment of male and female sexual dysfunction.

By staff writers
November 20, 2002

Related Reading

Palatin’s revenues down, losses up in fiscal 2002, October 1, 2002

Palatin adds to war chest, August 2, 2002

Palatin, Mallinckrodt restructure deal, May 15, 2002

Palatin raises $11 million, November 12, 2001

LeuTech to be tested for anthrax detection utility, November 5, 2001

Copyright © 2002

Page 1 of 3565
Next Page